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INTRODUCTION
Dermatomyositis (DM) and polymyositis (PM) are two major
idiopathic inflammatory myopathies (IIMs), which mainly affect
skin, muscle, lung (1, 2). The estimated annual incidence of PM/
DM ranges from 6 to 10 per million (3). Traditionally, PM associ-
ated interstitial lung disease (ILD) have been thought to have a
chronic clinical course (4, 5). Recently, autoantibodies against ami-
noacyl - tRNA synthetases (ARS) have been shown to indicate a
subacute course and good prognosis (6, 7). In contrast, some pa-
tients with ILD associated with DM, especially those with clinically
amyopathic dermatomyositis (CADM), who have the typical rash
of DM with little or no definite muscle symptoms or hypomyopathic
DM which mild muscle weakness with no elevation of muscle
enzyme for6 months who have anti melanoma differentiation-
associated gene (MDA)-5 antibody present with rapid progressive
disease and have a poor prognosis (7-9). Approximately one-
third of the patients with DM, CADM, PM develop ILD (4, 10) and
acute severe forms of ILD sometimes occur in DM or CADM pa-
tients. Therefore, ILD is an important extra-muscular manifesta-
tion of IIMs (11, 12), which causes substantial morbidity and re-
sults in up to 50% of mortality (13). The spectrum of IIMs ranges
from a mild chronic course to a fulminant rapidly progressive
course (14, 15). Some reports have described clinical characteris-
tics of ILD associated with PM or DM, but little is known about the
clinical, laboratory and radiological findings of each phenotype,
including myositis specific antibodies such as anti ARS autoanti-
body and anti MDA-5 antibody, which havebeen recently shown to
have associations with these diseases (16). The aim of this retro-
spective study was to evaluate clinical and radiological characteris-
tics of PM/DM patients according to autoantibody status.
METHODOLOGY
Study population
We retrospectively identified ILD patients from 2000 April to 2017
December at Okinawa Chubu Hospital, and determined whether
anti ARSantibody or anti MDA-5 antibody were present. The diag-
nosis of PM/DM was based on the criteria of Bohan and Peter
(1). 1) systemic muscle weakness, 2) increased serum muscle en-
zyme levels, 3) electromyographic (EMG) evidence of myopathic
changes, 4) typical histologic findings in muscle biopsies, and/or
5) characteristic dermatologic manifestations of DM. CADM, or
dermatomyositis sine myositis defined by the absence of clinically
significant muscle symptoms and normal muscle enzymes such as
creatine kinase (CK) for periods of6 months. CADM is associ-
ated with an acute severe forms of ILD (7, 9, 12, 15, 16). Baseline
clinical parameters including pulmonary function testing (PFT),
and radiological findings werecollected from the time of diagnosis.
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We included PM/DM patients who had parenchymal shadow and
were screened autoantibodies, including anti -Jo-1 antibody at
least. PM/DM patients without interstitial pneumonia were ex-
cluded.
Clinical information
We reviewed clinical symptoms such as fever, cough, dyspnea,
myalgia, arthralgia, Raynaud phenomenon, and physical findings
such as mechanic hand, rash, subungual erythema, erythema,
heliotrope rash, Gottron’s sign, and finger swelling. We collected
laboratory results for WBC, CRP, CPK, GOT, GPT, ALP, LDH,
Krebs von den Lungen-6 (KL-6),and ferritin. Auto-antibodies in-
cluding anti -Jo-1 (17, 18) other anti ARS antibody and anti -mela-
noma differentiation-associated gene 5 (MDA-5) antibody were
measured (19, 20). In physiological findings, we reviewed forced
vital capacity (FVC), percent predicted FVC, total lung capacity
(TLC), and percent predicted TLCs. The interval between PFT and
chest high resolution computed tomography (HRCT) was within
three months.
We evaluated disease activity on the basis of degree of muscle
inflammation such as serum GOT and ILD activity with extent of
parenchymal shadow.
Autoantibody measurement
Anti -ARS antibody was measured by [35S]methionine- labelled
protein immunoprecipitation (IPP) using extracts of HeLa cells
and by RNA-IPP using NET-2 buffer (50 mM TrisHCl at pH 7.5,
150 mM NaCl, 0.05% NP-40) (21, 22).
Radiological findings
Non-contrast chest HRCT findings were reviewed. These im-
ages comprised 1.5 mm collimation sections at 10 mm intervals. We
evaluated for consolidation, ground-glass opacity (GGO), reticular
shadow, traction bronchiectasis and lung tip consolidation at
below 1 cm of right diaphragm. Evaluation field were six which
including carina, right inferior pulmonary vein, and below 1 cm of
right diaphragm of both lungs. Ground-glass opacity was defined if
there was hazy increased attenuation of the lung that did not ob-
scure the underlying vessels. Consolidation was defined as ho-
mogeneous increase in pulmonary parenchymal attenuation that
obscured the underlying vessels. Reticular shadow was defined as
regular interlacing linear shadows separated by a few millimeters.
Traction bronchiectasis was defined as Irregular bronchial dilata-
tion within or around areas with parenchymal abnormalities such
as consolidation or GGO. Definition of lung tip consolidation was
thick consolidation2 mm with connection of both right dia-
phragm and pleura (23). Extent of consolidation, GGO, reticular
shadow, traction bronchiectasis was categorized as follows ; 0 :
none, 1 :25%, 2 : 25%50%, 3 : 50%75%, 4 :75% (24).The
extent of lung tip consolidation was defined as 0 : none, 1 : one
thick consolidation, 2 : more than two thick consolidations. A thick
consolidation was defined as one that measured more than 2 mm.
The score of each findings was defined as total sum divided into six.
Treatment protocol
We commenced systemic prednisolone 0.51.0 mg/kg/day or
plus cyclosporine or tacrolimus with monitoring trough value.
Once disease stabilized, we tapered prednisolone every 2 or 4
weeks. When we saw progressive disease, we started intravenous
methyl -prednisolone 1 g/day consecutive 3 days plus cyclosporine
or tacrolimus and intravenous cyclophosphamide.
This study was approved by the institutional Review Board
Board at Okinawa Chubu Hospital with a waiver of informed con-
sent to allow the retrospective study of de- identified data.
Statistical analysis
Continuous variables are presented as median (min, max) or
meansstandard deviations, as appropriate. Categorical variables
are presented as percentages. Chi -square and Fisher’s exact tests
were used to analyze categorical data, and Kruskal -Walls rank
tests were used for continuous data. Pearson correlation coefficient
were calculated for each laboratory value and radiological finding.
KaplanMeier survival curves and the log-rank tests were used to
evaluate survival. The level of statistical significance was set at p
0.05. All analyses were performed using STATA version 11.0 ;
(Stata Corp., College Station, TX, USA).
RESULTS
Baseline clinical differences among the PM/DM associated ILD
patients based on the autoantibody status
We identified 52 ILD patients with PM or DM. The clinical
characteristics are organized in Table 1 according to the autoanti-
body status. Among anti ARS antibody group, Jo-1 were 14, PL-7
were 2, KS was 1 and OJ was 1. Median age was around 50 and
69.2% were female. Cough was slightly more frequent in anti
MDA-5 group, but this was not statistically significant (p=0.062).
Rash, subungual erythema, splinter hemorrahge, erythema,
Gottron’s sign and heliotrope rash were seen more often in anti
MDA-5 group (p=0.016, 0.003, 0.001, 0.013, and 0.004, respec-
tively). Survival in the anti MDA-5 group was decreased compared
with that of other two groups. (1.00 vs 84.3 and 22.9 months, p
0.001) (Table 1).
Table 1. Clinical characteristics of three groups at diagnosis
Antibody
unknown
(n=30)
Anti -ARS
antibody
(n=18 :
Anti - Jo -1
14, Anti PL-7
2, Anti KS 1,
Anti OJ 1)
Anti -
MDA-5
antibody
(n=4)
p -value
Age 55.5 (17, 80) 60.5 (26, 76) 45.5 (23, 55) 0.135
Gender (M/F) 9/21 6/12 1/3 0.940
Smoking (Pack-year) 0 (0, 1400) 13.8 (0, 45) 27 (0, 90) 0.245
Fever (%) 30 38.9 50 0.661
Cough (%) 26.7 55.6 75 0.051
Dyspnea (%) 40 55.6 75 0.316
Myalgia (%) 66.7 44.4 25 0.147
Arthralgia (%) 33.3 27.8 50 0.693
Raynaud (%) 6.7 5.6 0 0.867
Rash (%) 63.3 16.7 100 0.001
Subungual erythema (%) 26.7 11.1 100 0.002
Splinter Hemorrahge(%) 13.3 11.1 50 0.139
Mechanic Hand (%) 16.7 11.1 0 0.621
Erythema (%) 46.7 16.7 100 0.006
Gottron’s Sign (%) 36.7 5.6 100 0.001
Heliotrope Rash (%) 26.7 0 75 0.003
Sausage Finger (%) 26.7 5.6 75 0.010
Initial PSL dose (mg/day) 40.119.6 44.415.9 52.59.6 0.292
Combination therapy (%) 40 66.7 75 0.711
Survival time (months) 84.3 22.9 1.00 0.001
Definition of abbreviation : M=men ; F=female ; ARS=aminoacyl - tRNA
synthetases ; MDA-5=melanoma differentiation-associated gene 5 ;
PSL=prednisolone.
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Laboratory findings : WBC was significantly elevated in the anti-
ARS antibody group (p=0.001). Both CRP and KL-6 tended to be
elevated in anti -ARS antibody and ferritin tended to show high
value. However, there were no statistically significance (Table 2).
Pulmonary function test
Baseline median FVC and %FVC of anti -ARS antibody group
tended to show more restrictive disorders[1.49 (0.95, 1.75) vs 1.89
(1,19, 3.48), p=0.051][60.8 (44.8, 79.5) vs 70.9 (60.7, 100.6), p=
0.078]compared to that of antibody negative group.
Imaging
The extent of GGO, consolidation, and lung tip consolidation
were significantly increased in anti MDA-5 group (p=0.051, p=
0.026, and p=0.027, respectively) (Table 3).
Representative imaging of reticular shadow, traction bronchiecta-
sis and lung tip consolidation are shown in Figure1, Figure 2 and
Figure 3. Among four anti MDA-5 antibody associated ILD pa-
tients, all but one had lug tip consolidation.
CorrelationAnalyses
WBC and CRP (r=0.481, p=0.001), GOT and ferritin (r=0.496. p=
0.019), and anti MDA-5 antibody and lung tip consolidation (r=
0.435, p=0.009) were all weakly correlated. Reticular shadow and
tractionbronchiectasis (p=0.633, p0.001) consolidation andGGO
(r=0.668, p0.001)weremoderately correlated. GOTwas strongly
correlated with both CPK (r=0.889, p0.001) and LDH (r=0.910, p
0.001)(Table 4). In addition, GOT value of 7 death patients out
of10showedover100IU/Latdiagnosis.
Treatment
18 (60%) of the antibody negative group received prednisolone
alone. On the other hand, 12(67%) of the patients in the anti ARS
associated ILD group received prednisolone with other immuno-
suppressants, such as cyclosporine A or tacrolimus. 3(75%) of the
patients in the anti MDA-5 associated ILD group received intensive
therapy consisting of pulse corticosteroids, tacrolimus and intrave-
nous cyclophosphamide (IVCY). In maintenance therapy, anti ARS
antibody positive ILD patients were more likely to be treated with
prednisolone only (54.5% vs 33.3%) and antibody negative patients
more likely to receive prednisolone plus tacrolimus (38.9% vs 9.1%).
Among 48 patients except for anti -MDA-5 patients, 6 patients
showed relapse. And 4 out of 6 relapse patients showed over
100 IU/L of serum GOT at diagnosis. Two anti -MDA-5 antibody
positive patients died within a month despite intensive therapy.
Kaplan-Meier survival curves show decreased survival in the anti
MDA-5 associated ILD group, compared to other two groups (1.0
months vs 79.7 and 23.7 months, p0.001). (Figure 4) Among 48
Table 2. Laboratory findings according to antibody status at diag-
nosis
Antibody
unknown
(n=30)
Anti -ARS
antibody
(n=18)
Anti -MDA-5
antibody
(n=4)
p-value
WBC
(3300-8600/mm3)
8700
(3700, 16900)
13100
(4900, 21500)
5025
(3600, 8100)
0.001
CRP
(0.00 -0.14 mg /dl)
0.8
(0, 6.8)
3.8
(0.01, 22.6)
1.4
(0.2, 5.6)
0.133
GOT(13-30 U/ L) 41 (15, 1034) 61 (17, 251) 95 (56, 116) 0.824
GPT(10-42 U/ L) 28 (8, 510) 50 (13, 300) 63 (12, 105) 0.525
CPK(59-248 U/ L) 1079
(30, 29830)
774
(37, 7810)
366
(44, 2107)
0.330
LDH
(124-222 U/ L)
490
(169, 2790)
547
(177, 1093)
499
(366, 832)
0.903
KL-6
(105-435 U/ mL)
860
(272, 3650)
909
(169, 9100)
549
(455, 1342)
0.553
Ferritin
(30 -400 ng/ mL)
981
(46, 2958)
308
(34, 1096)
512
(172, 852)
0.222
SS-A (%) 13.3 33.3 0 0.146
Definition of abbreviation : ARS=aminoacyl - tRNA synthetases ; MDA-
5= melanoma differentiation-associated gene 5 ; WBC=white blood
cell ; CRP=C-reactive protein ; CPK=creatine phosphokinase ; LDH=
lactate dehydrogenase ; KL-6=Krebs von den Lungen-6.
Findings are presents as median (interquartile range)
Table 3. Radiological findings of three groups at diagnosis
Antibody
Unknown
(n=30)
Anti -ARS
antibody
(n=18)
Anti -MDA-5
antibody
(n=4)
p-value
GGO 2 (0, 3) 2 (0, 4) 2.5 (2, 4) 0.051
Consolidation 1 (0, 4) 1 (0, 4) 3.5 (2, 4) 0.026
Reticular
shadow
0 (0, 3) 1 (0, 2) 0.5 (0, 2) 0.203
Traction
bronchiectasis
0 (0, 2) 0 (0, 2) 0 (0, 2) 0.667
Lungtip
consolidation
0 (0, 2) 0 (0, 2) 2 (0, 2) 0.027
Definition of abbreviation : ARS=aminoacyl - tRNA synthetases ; MDA5=
melanoma differentiation-associated gene 5 ; GGO= ground glass
opacity. Findings are presented as median (interquartile range)
Figure 1. 60-year -old woman of anti PL-7 antibody with reticular
shadow
Subpleural reticular shadow were demonstrated.
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patients who survived acute phase, 6 patients relapsed. Overall, ten
patients died during observation period. 4 anti MDA-5 positive
patients died from progressive respiratory failure, and 5 patients
died from infection and 1 patients died from cancer. And 2 MDA-5
patients were deceased within 1 month from commencing treat-
ment. (Table 5)
DISCUSSION
We described the clinical characteristics, laboratory findings,
radiological findings and correlations between laboratory and ra-
diological findings in a series of 52 PM/DM patients, according to
their autoantibody status. Cough, rash, subungual erythema, splin-
ter hemorrahge, erythema, Gottron’s sign, and heliotrope rash
were more often seen in anti MDA-5 group, who also had more
extensive shadow involving of central bronchi and experienced
cough more frequently compared to other two groups. In addition,
all four anti MDA-5 positive patients satisfied clinical criteria of
Figure 2. 70-year -old woman of Anti Jo -1 antibody with traction bron-
chiectasis
Traction bronchiectasis were evident in peribronchovascular bundle.
Figure 3. 22-year -old woman of anti MDA-5 antibody with lung tip
consolidation
Lung tip consolidation was shown in edge of right diaphragm.
Table 4. Correlation coefficients among clinical parameters
WBC r=0.481 CRP
GOT r=0.889 CPK
LDH r=0.910 GOT
Ferritin r=0.496 GOT
anti MDA-5 antibody r=0.435 Lung tip consolidation
Consolidation r=0.668 GGO
Reticular shadow r=0.633 Traction bronchiectasis
Definition of abbreviation : WBC=white blood cell ; CRP=C-reactive
protein ; CPK=creatine phosphokinase ; LDH=lactate dehydrogenase ;
KL-6=Krebs von den Lungen-6 ; GGO=ground glass opacity.
Figure4. Kaplan-Meier survival curve
Anti MDA-5 antibody positive patients showed statistically significant
poor survival compared to other two groups. (Log rank = p0.001)
Table 5. Cause of death and interval from initial treatment
Antibody Type Cause of Death
Interval from In-
itial treatment
(months)
Case 1 89y F Unknown Pneumonia 152.4
Case 2 44y F Unknown Pneumonia 12.2
Case 3 80y F Unknown Pneumonia 1.9
Case 4 80y M Unknown Pneumonia 8.6
Case 5 50y M MDA-5 Respiratoryfailure 0.3
Case 6 41y F MDA-5 Respiratoryfailure 2.7
Case 7 57y F Unknown Cancer 15.8
Case 8 56y F Unknown Pneumonia 1.0
Case 9 56y F MDA-5 Respiratoryfailure 1.3
Case 10 23y F MDA-5 Respiratoryfailure 0.7
Definition of abbreviation : y=year -old ; M=male ; F=female ; MDA5=
melanoma differentiation-associated gene 5.
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dermatomyositis, with multiple skin manifestations. WBC and
CRP were elevated patients with anti -ARS antibody, suggesting a
higher degree of inflammation in these patients. KL-6 was also ele-
vated in anti -ARS antibody group, which had reduced lung volume
based on FVC and chest HRCT (25-27). Therefore, elevated KL-6
might reflect chronic volume loss with fibrosis. Alternatively, low
KL-6 levels were associated with the more acute disease process in
anti MDA-5 positive patients. KL-6 is a high molecular weight
protein, so induction of KL-6 by epithelial injury and fibrosis may
not be able to occur within the limited survival of MDA-5 positive
patients. Among radiological findings, significant lung tip consoli-
dation was seen exclusively in anti MDA-5 positive patients, and
only minimally present among ILD patients that were anti MDA-5
antibody negative. The more extensive lung tip consolidation of
anti MDA-5 antibody positive ILD patients limited diaphragmatic
excursion and decreases overall lower lung field volume (23).
Based on these findings, we now provide early, high- intensive
treatment to patients with lung tip consolidation, hoping to avoid
progressive limitation of the smooth movement of right dia-
phragm. In addition, the removal of exudates in the basal area is
more dependent upon gravity and respiratory movement, so per-
sistent inflammation or fibrosis can lead to severe restrictive disor-
ders or profound dyspnea. Among laboratory values, GOT had
strong positive correlation with CPK and LDH, but not ferritin,
which suggests that muscle dysfunction, inflammation and cell
lysis play an important role. We could not demonstrate an associa-
tion between serum ferritin and mortality, which has been re-
ported in prior studies, especially in anti MDA-5 associated ILD
patients (27, 28). The mechanism of inflammation or disease his-
tory in our patients might differ. Our results suggest that common
laboratory assays for GOT, CPK and LDH are useful for analyzing
disease activity in both antibody negative and anti ARS positive
antibody associated ILD patients. However, high-risk patients with
anti MDA-5 antibody frequently do not have CPK elevation, which
should encourage rapid and comprehensive evaluation of ILD pro-
gression (28-31).
In serum biomarker, Chen,et al. reported that serum KL-6 was
useful predictor of disease progression and treatment response of
PM/DM ILD patients (32). KL-6 is associated with typealveolar
cell injury and extent of fibrosis. Therefore, decrease KL-6 might
be associated with improvement of lung parenchymal shadow. We
did not check serum KL-6 of PM/DM ILD patients in our cohort
repeatedly. So, trace of serial KL-6 of PM/DM ILD patients war-
rants future study in Japan.
We noted that the. initial prednisolone dosage was somewhat
higher in anti MDA-5 positive or anti ARS positive ILD patients
compared to antibody negative ILD patients, but this was not statisti-
cally significant. In addition, both anti MDA-5 positive and anti ARS
positive ILD patients were more likely to receive combination
therapy compared to antibody negative patients, although this dif-
ference was also not significant. Patients with anti -ARS antibody
often have relapse of ILD (32, 33). Therefore, meticulous clinical
monitoring of symptoms, biomarkers, and radiological findings, is
essential. Anti ARS antibody positive ILD patients often have re-
lapse of parenchymal shadow in the same anatomical location as
the original infiltrate. Among our anti ARS antibody positive ILD pa-
tients, prednisolone with tacrolimus was more likely to stabilize
clinical condition (34). Our ILD patients with anti MDA-5 antibody
had a poorer prognosis in our study, which is consistent with prior
reports (35-40). Patients with anti -MDA-5 antibody should there-
fore start intensive therapy as soon as possible. ILD patients with
anti MDA-5 antibody who survive the acute phase seldom have
been reported to relapse. Therefore, control of disease activity of
acute phase is crucial for these high-risk ILD patients with anti
MDA-5 antibody. Among 48 patients who survived acute phase, 6
patients relapsed despite slow tapering of systemic prednisolone.
These patients often relapsed under 20 mg of prednisolone. There-
fore, meticulous monitoring of disease activity and sensible use of
immunosuppressants are required.
The strength of this study is the detailed clinical information ob-
tained on patients from a large ILD program. Certain limitations are
worth noting. This was s single-center retrospective study, and
may not therefore generalize to all PM/DM ILD patients. However,
the clinical signs and symptoms of our patients were comparable
with previous reports. Secondly, we lack results for ferritin and new
anti -ARS autoantibody for some of our older cases. However,
anti Jo-1 antibody was screened for every patient. It is therefore
possible that the associations of these tests may have been dif-
ferent if those data were not missing. We also lack PFT in some of
the anti MDA-5 associated ILD patients, because of rapid progres-
sion and limited survival. Finally, the HRCT performed in our pro-
gram is not uniformly available in all hospitals, so coordination
between referral clinic and special center is important.
In conclusion, ILD patients with anti MDA-5 antibody have a
poor prognosis. Cough and leukocytosis are useful indicators,
especially in patients with anti ARS antibodies. Muscle enzyme
levels such as GOT, CPK and LDH have strong associations with
the acute phase of both antibody negative and anti ARS antibody
positive ILD patients. Multi center studies are needed to evaluate
the clinical findings and define the course of PM/DM ILD patients
based on autoantibody status.
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